COVID-19 infection, and reinfection, and vaccine effectiveness against symptomatic infection among health care workers in the setting of omicron variant transmission in New Delhi, India.
Covaxin
India
Omicron variant
Reinfection
Symptomatic infection
Vaccine effectiveness
Journal
The Lancet regional health. Southeast Asia
ISSN: 2772-3682
Titre abrégé: Lancet Reg Health Southeast Asia
Pays: England
ID NLM: 9918419282806676
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
pubmed:
1
7
2022
medline:
1
7
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
Surge of SARS CoV-2 infections ascribed to omicron variant began in December 2021 in New Delhi. We determined the infection and reinfection density in a cohort of health care workers (HCWs) along with vaccine effectiveness (VE) against symptomatic infection within omicron transmission period (considered from December 01, 2021 to February 25, 2022. This is an observational study from the All India Institute of Medical Sciences, New Delhi. Data were collected telephonically. Person-time at risk was counted from November 30, 2021 till date of infection/ reinfection, or date of interview. Comparison of clinical features and severity was done with previous pandemic periods. VE was estimated using test-negative case-control design [matched pairs (for age and sex)]. Vaccination status was compared and adjusted odds ratios (OR) were computed by conditional logistic regression. VE was estimated as (1-adjusted OR)X100-. 11474 HCWs participated in this study. The mean age was 36⋅2 (±10⋅7) years. Complete vaccination with two doses were reported by 9522 (83%) HCWs [8394 (88%) Covaxin and 1072 Covishield (11%)]. The incidence density of all infections and reinfection during the omicron transmission period was 34⋅8 [95% Confidence Interval (CI): 33⋅5-36⋅2] and 45⋅6 [95% CI: 42⋅9-48⋅5] per 10000 person days respectively. The infection was milder as compared to previous periods. VE was 52⋅5% (95% CI: 3⋅9-76⋅5, Almost one-fifth of HCWs were infected with SARS CoV-2 during omicron transmission period, with predominant mild spectrum of COVID-19 disease. Waning effects of vaccine protection were noted with increase in time intervals since vaccination. None.
Sections du résumé
Background
UNASSIGNED
Surge of SARS CoV-2 infections ascribed to omicron variant began in December 2021 in New Delhi. We determined the infection and reinfection density in a cohort of health care workers (HCWs) along with vaccine effectiveness (VE) against symptomatic infection within omicron transmission period (considered from December 01, 2021 to February 25, 2022.
Methods
UNASSIGNED
This is an observational study from the All India Institute of Medical Sciences, New Delhi. Data were collected telephonically. Person-time at risk was counted from November 30, 2021 till date of infection/ reinfection, or date of interview. Comparison of clinical features and severity was done with previous pandemic periods. VE was estimated using test-negative case-control design [matched pairs (for age and sex)]. Vaccination status was compared and adjusted odds ratios (OR) were computed by conditional logistic regression. VE was estimated as (1-adjusted OR)X100-.
Findings
UNASSIGNED
11474 HCWs participated in this study. The mean age was 36⋅2 (±10⋅7) years. Complete vaccination with two doses were reported by 9522 (83%) HCWs [8394 (88%) Covaxin and 1072 Covishield (11%)]. The incidence density of all infections and reinfection during the omicron transmission period was 34⋅8 [95% Confidence Interval (CI): 33⋅5-36⋅2] and 45⋅6 [95% CI: 42⋅9-48⋅5] per 10000 person days respectively. The infection was milder as compared to previous periods. VE was 52⋅5% (95% CI: 3⋅9-76⋅5,
Interpretation
UNASSIGNED
Almost one-fifth of HCWs were infected with SARS CoV-2 during omicron transmission period, with predominant mild spectrum of COVID-19 disease. Waning effects of vaccine protection were noted with increase in time intervals since vaccination.
Funding
UNASSIGNED
None.
Identifiants
pubmed: 35769163
doi: 10.1016/j.lansea.2022.100023
pii: S2772-3682(22)00028-2
pmc: PMC9167830
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100023Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
We declare no competing interests.
Références
Nat Med. 2022 May;28(5):1063-1071
pubmed: 35189624
Vaccine. 2021 Jul 5;39(30):4013-4024
pubmed: 34119350
Vaccines (Basel). 2022 Mar 17;10(3):
pubmed: 35335091
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263
pubmed: 35176007
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Indian J Med Ethics. 2021 Jan-Mar;VI(1):1-12
pubmed: 34080993
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Trans R Soc Trop Med Hyg. 2022 Mar 2;116(3):242-251
pubmed: 34339514
EBioMedicine. 2022 Apr;78:103938
pubmed: 35305396
J Med Virol. 2022 Jul;94(7):2969-2976
pubmed: 35246846
JAMA Netw Open. 2022 Jan 4;5(1):e2142210
pubmed: 34994793
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Elife. 2020 Aug 21;9:
pubmed: 32820721
ERJ Open Res. 2021 Jun 07;7(2):
pubmed: 34104643
Euro Surveill. 2013 Sep 12;18(37):
pubmed: 24079398